Dihexa peptide: cognitive enhancement guide

Key takeaways

• Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic peptide derived from angiotensin IV, developed at Washington State University
• Researchers described it as being up to 10 million times more potent than BDNF at stimulating new synapse formation via the HGF/c-Met receptor system
• Key published studies from the original research group have received expressions of concern or been retracted as of 2025
• No human clinical trials have been conducted or registered
• Dihexa is not FDA-approved and carries significant uncertainty given the retraction of foundational research

What is dihexa?

Dihexa is a modified peptide built from the angiotensin IV molecule. It was developed by Joseph Harding and John Wright at Washington State University as part of a decades-long research program into the cognitive effects of the renin-angiotensin system. The peptide’s full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide.

The research program began with an observation: angiotensin IV, a fragment of the blood pressure hormone angiotensin II, appeared to improve memory and learning in animal models. The problem was that angiotensin IV broke down too quickly in the body to be useful. Dihexa was designed as a metabolically stable version that could cross the blood-brain barrier and last long enough to produce measurable cognitive effects [1].

Among the peptides studied for cognitive function, dihexa generated outsized attention because of the extraordinary potency claims. But understanding where this research stands today requires a careful look at the publication record.

How does dihexa work?

Dihexa’s proposed mechanism centers on the hepatocyte growth factor (HGF) / c-Met receptor system. HGF is a protein that promotes cell growth, survival, and the formation of new synaptic connections. The c-Met receptor mediates these effects in the brain.

Wright and Harding proposed that angiotensin IV and its analogs (including dihexa) activate the HGF/c-Met system, leading to synaptogenesis, the creation of new connections between neurons. In their 2015 review published in the Journal of Alzheimer’s Disease, they outlined how this pathway could theoretically treat neurodegenerative conditions by rebuilding lost synaptic networks [2].

A 2015 review in Progress in Neurobiology detailed the rational drug design process. The researchers systematically modified the angiotensin IV molecule to improve metabolic stability, blood-brain barrier penetration, and oral bioavailability, producing dihexa and related compounds [3].

The mechanism is distinct from most nootropic peptides. Rather than modulating neurotransmitter levels or receptor sensitivity, dihexa was proposed to stimulate the physical growth of new synaptic connections. This is what made the “10 million times more potent than BDNF” claim so striking: it referred specifically to binding affinity at HGF/c-Met for promoting synapse formation, not a general measure of cognitive benefit.

The research and its complications

The original findings

The first major publication appeared in 2013 in the Journal of Pharmacology and Experimental Therapeutics. McCoy et al. reported that dihexa reversed cognitive deficits in aged rats and in rats given scopolamine (a drug that impairs memory). The effects were dose-dependent and persisted after the drug was cleared [4].

A 2014 follow-up by Benoist et al. in the same journal provided the mechanistic data. This paper reported the “10 million times more potent than BDNF” finding and showed that dihexa’s procognitive and synaptogenic effects depended on HGF/c-Met activation [5].

Retractions and expressions of concern

This is where the story gets complicated. The 2014 Benoist paper (PMID 25187433) was retracted in 2025 [5]. The 2013 McCoy paper (PMID 23055539) received an expression of concern in 2021 [4]. These are serious red flags in scientific publishing.

A retraction means the journal no longer stands behind the paper’s findings. Expressions of concern indicate the journal identified problems worth investigating. The specific reasons for these actions are detailed in the retraction notices, but the practical result is the same: the two foundational papers supporting dihexa’s mechanism and efficacy are no longer considered reliable by the scientific community.

What remains

An independent 2018 systematic review of angiotensin IV cognitive benefits (Ho and Nation, published in Neuroscience and Biobehavioral Reviews) examined the broader class of angiotensin IV analogs. The review found consistent evidence across studies that angiotensin IV and its derivatives improved cognitive performance in animal models, but noted the field’s heavy reliance on a small number of research groups [6].

A 2024 study in the Journal of Huntington’s Disease tested an angiotensin IV analog (related to but not identical to dihexa) in a Huntington’s disease rat model and found it reduced some disease-like symptoms [7]. This suggests the HGF/c-Met pathway remains a legitimate research target, even if the specific dihexa data is compromised.

The HGF/c-Met system itself is well-established in neuroscience. Its role in neuroprotection, neural development, and synaptic plasticity is supported by research from many independent groups. The question is specifically whether dihexa activates this system in the way originally claimed.

Benefits (claimed vs. supported)

Synapse formation

The claim that dihexa promotes synaptogenesis at extraordinarily low concentrations came from the now-retracted 2014 paper [5]. Without reliable data supporting this specific claim, it should be treated as unproven.

Memory improvement in aged animals

The 2013 rat study reported cognitive improvements, but this paper has an expression of concern [4]. The broader systematic review of angiotensin IV analogs supports the general concept that this drug class can improve memory in animal models [6].

Potential neuroprotective effects

The HGF/c-Met system is genuinely involved in neuroprotection. Wright and Harding’s 2015 review article, which discusses the theoretical framework rather than presenting new experimental data, remains unretracted and outlines the rationale for targeting this pathway in Alzheimer’s and Parkinson’s disease [2, 3].

Side effects and safety

The safety profile of dihexa is effectively unknown. No human toxicology studies have been conducted.

Theoretical concerns include:

Because HGF/c-Met signaling is involved in cell growth, there is a theoretical risk of promoting tumor growth. The c-Met pathway is overactive in several types of cancer. Whether dihexa’s activation of this pathway could contribute to tumor development has not been studied.

As an angiotensin IV derivative, cardiovascular effects are possible, though the peptide was designed to act primarily in the brain rather than on blood pressure.

The retraction of key papers adds a safety dimension beyond typical unknowns. When foundational mechanism data is unreliable, our understanding of what the drug actually does in the body becomes uncertain. This makes risk assessment nearly impossible.

Self-experimentation with dihexa carries risks that cannot be quantified based on current evidence. Our guide on peptide side effects covers general considerations, but dihexa’s specific risk profile is genuinely unknown.

Dosage and administration

No validated dosing protocol exists for humans. The animal studies used doses in the range of 0.01-2 mg/kg in rats, administered via various routes including oral, intracerebroventricular, and subcutaneous injection.

Self-experimenters in online communities have reported using sublingual and subcutaneous doses ranging from 10-40 mg, but these protocols have no scientific basis and the individuals are taking on unquantified risk, especially given the retracted research foundation.

Any use of dihexa should only occur under medical supervision through a physician familiar with peptide therapy and its limitations.

How to get dihexa

Dihexa is not FDA-approved, not prescribed by mainstream physicians, and not available through standard pharmacies. It exists in the same legal gray area as many research peptides.

Given the retractions affecting the foundational research, anyone considering dihexa should weigh the evidence situation carefully. Several other peptides for cognitive function have cleaner research records, including selank and semax.

For those interested in evidence-based cognitive support through peptide therapy, a consultation with a provider who can discuss alternatives would be more productive than pursuing a compound with compromised research backing.

Frequently asked questions

Is dihexa really 10 million times more potent than BDNF?▼

This claim came from a 2014 paper that was retracted in 2025 [5]. The comparison referred specifically to binding affinity at the HGF/c-Met receptor for promoting synapse formation, not overall cognitive potency. With the paper retracted, this claim is no longer supported by the peer-reviewed literature.

Why was the dihexa research retracted?▼

The 2014 Benoist et al. paper was formally retracted by the Journal of Pharmacology and Experimental Therapeutics in 2025. The 2013 McCoy et al. paper received an expression of concern in 2021. The specific concerns are documented in the retraction and expression of concern notices published by the journal.

Is dihexa safe?▼

The honest answer is that no one knows. No human safety studies have been conducted, and the retraction of mechanism papers means our understanding of what the compound does biologically is uncertain. The theoretical concern about c-Met pathway activation and cancer risk adds another layer of unknown.

Can you take dihexa orally?▼

The researchers designed dihexa specifically for oral bioavailability, and the animal studies used oral dosing among other routes. However, without human pharmacokinetic data, oral absorption and effective dosing in humans remain unestablished.

What are alternatives to dihexa for cognitive enhancement?▼

Peptides with better-established research profiles for cognitive support include selank (anxiolytic with nootropic effects), semax (BDNF modulator with clinical use in Russia), and cerebrolysin (brain-derived peptide mix with 30+ RCTs). For a broader overview, see our guide on peptides for cognitive function.

Is dihexa legal?▼

Dihexa is not a scheduled substance in the US but is also not FDA-approved. It falls into the research chemical category common to many experimental peptides. It can be purchased from research suppliers but cannot be legally marketed for human consumption.

Does dihexa cross the blood-brain barrier?▼

The peptide was specifically designed for blood-brain barrier penetration. Wright and Harding’s 2015 review describes the chemical modifications made to achieve this [3]. Whether these claims hold up given the broader research concerns is uncertain.

References

1. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26-46. PubMed
2. Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease. J Alzheimers Dis. 2015;45(4):985-1000. PubMed
3. Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015;125:26-46. PubMed
4. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. [Expression of concern published 2021] PubMed
5. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014;351(2):390-402. [RETRACTED 2025] PubMed
6. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209-225. PubMed
7. Wells RG, Azzam AF, Hiller AL, Sardinia MF. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington’s Disease-Like Symptoms in Rats. J Huntingtons Dis. 2024;13(1):55-66. PubMed